-
SAN FRANCISCO Big medical companies usually have big footprints at medical conferences, and Medtronic stomped around with one of the very largest CD&D has ever seen at this year's scientific sessions of the Heart Rhythm Society (HRS; Washington).
-
Medtronic (Minneapolis) in mid-June received FDA approval of its Attain StarFix OTW (over-the-wire) lead. The company said it's the first active fixation left-heart lead for cardiac resynchronization therapy (CRT) and that the lead has demonstrated a 0% chronic (meaning more than one day post-implant) dislodgement rate.
-
It takes a team to change the high-risk lifestyle habits of a single individual according to a large-scale study conducted by the European Society of Cardiology (ESC; Sophia Antipolis, France) published in the June 14 issue of The Lancet.
-
Applera; Celera; Berkeley HeartLab; Abbott Laboratories; Applied Biosystems; Invitrogen; Escalon Medical; Drew Scientific; JAS Diagnostics; Kardia Health Systems; Freeland Systems; Pediatrix Medical Group
-
In a move that could help offset its $458 million 4Q07 Gudiant-related losses, Boston Scientific (Natick, Massachusetts) reported last month that it had signed a definitive agreement to sell its investments in a portfolio of companies, subject to certain closing and other conditions, to Saints Capital (San Francisco), a secondary direct-investment firm.
-
Cook Medical; HealthTrust Purchasing Group; Freescale Semiconductor; Monebo Technologies; HemCon Medical Technologies; SanguiBioTech; LifeScan; ResMed; Johnson & Johnson; IDev Technologies; YMed; Positron; Disease Management; NuView Radiopharmaceuticals
-
After more than two years of clinical data linking drug-eluting stents (DES) with an increased risk of stent thrombosis compared to their bare-metal cousins, a study in the Journal of the American Medical Association (JAMA) may shed some positive light on the DES space.
-
BARCELONA, Spain EuroPCR, a prestigious meeting organized by the European Association of Percutaneous Cardiovascular Interventions (EAPCI), an association of the European Society of Cardiology (Sophia Antipolis, France) and a group focused on interventional devices used for diagnosis and treatment of cardiovascular disease, is the leading interventional meeting in Europe and an important forum for introducing new devices.
-
SAN FRANCISCO Remote monitoring of implanted cardiac devices is hot at least at the level of discussion during scientific conferences, if not at the level of reimbursement of such services. But one step at a time: This technology clearly is adding more evidence concerning efficacy, if not clear cost-effectiveness.
-
Despite the fact that it is the only FDA-approved drug to treat ischemic stroke, Activase, also known as tissue plasminogen activator (tPA), a product from Genentech (South San Francisco, California) is not used in the majority of cases for which it is approved.
